Clinical Trial Update: Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pembrolizumab plus platinum-based chemotherapy with or without canakinumab in untreated locally advanced or metastatic non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Canakinumab (canakinumab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: TERMINATED | Results posted: 2024-10-08